GT Biopharma, Inc. (GTBP) - 10-K Filing Summary
Business Context and Reporting Period
Company: GT Biopharma, Inc.
Filing Type: Annual Report on Form 10-K
Period Ended: December 31, 2024
Business Overview: GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® platforms. These therapies harness natural killer (NK) cells to target cancer cells. The company operates as a fully remote entity as of July 1, 2024, with no physical headquarters.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.2) million | $(7.6) million |
| Operating Expenses | $14.4 million | $13.6 million |
| Cash and Cash Equivalents (End of Period) | $4.0 million | $1.1 million |
| Net Cash Used in Operating Activities | $(12.9) million | $(8.9) million |
| Working Capital (Deficit) | $(1.7) million | $7.4 million |
| Stockholders' Equity (Deficit) | $(1.7) million | $7.5 million |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $5.6 million (73%) year-over-year. This was primarily driven by a decrease in the non-cash gain from the change in fair value of warrant liability (from $4.8 million in 2023 to $0.8 million in 2024) and a significant increase in Selling, General, and Administrative (SG&A) expenses.
- SG&A Expenses: Increased by $3.4 million (70%) to $8.3 million, largely due to higher legal fees and settlement expenses related to ongoing litigation.
- R&D Expenses: Decreased by $0.7 million (10%) to $5.8 million, attributed to reduced project material costs, partially offset by increased scientific research costs.
- Stock Compensation: Decreased significantly by $2.0 million (90%) to $0.2 million.
- Liquidity Position: While cash balances increased to $4.0 million due to the sale of short-term investments and a registered direct offering in May 2024, the company moved from a positive working capital position in 2023 to a deficit of $1.7 million in 2024.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that the company's financial condition raises substantial doubt about its ability to continue as a going concern. Management believes existing cash resources are insufficient to fund operations for one year from the filing date without additional financing.
Outlook and Pipeline:
- GTB-3650: The lead candidate targeting CD33 for AML/MDS. The FDA cleared the IND in June 2024, and patient enrollment began on January 21, 2025.
- GTB-5550: A B7-H3 targeted TriKE for solid tumors. Preclinical studies are ongoing with a GMP manufacturing campaign initiated.
- GTB-3550: Development suspended to focus resources on second-generation camelid nanobody TriKEs.
Key Risks and Contingencies:
- Nasdaq Delisting Risk: On November 21, 2024, Nasdaq notified the company that stockholders' equity fell below the $2.5 million minimum requirement. The company submitted a compliance plan on December 31, 2024, but delisting remains a risk if compliance is not achieved.
- Legal Proceedings:
- Ohri Matter: Arbitration against former CFO Manu Ohri for breach of fiduciary duties; hearing scheduled for June 2025.
- TWF Global/Z-One Matter: Dispute regarding convertible promissory notes and share registration. A new summons was filed by Z-One in February 2025.
- Handelman Matter: Arbitration against former CFO Michael Handelman resulted in a favorable award for the company ($473k legal fees + return of shares), but collectability is uncertain.
- Capital Needs: The company requires additional capital to continue operations and clinical development. Failure to secure funding could force delays or elimination of programs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.0 million cash balance against the stated need for additional financing within the next 12 months.
- Nasdaq Compliance: Monitor the status of the compliance plan submitted to Nasdaq to avoid delisting of the GTBP ticker.
- Related Party Transactions: Review the concentration of expenses with Cytovance Biologics, Inc. (a related party holding ~9.8% of stock), which accounted for significant R&D spend and accounts payable.
- Legal Exposure: Assess the potential financial impact of the pending arbitration with Manu Ohri and the new lawsuit filed by Z-One LLC.
- Clinical Milestones: Track the enrollment progress and safety data for the GTB-3650 Phase 1 trial, which commenced in January 2025.